Tirzepatide and semaglutide sold via TikTok comments: what's real
Quick answer
The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims. Both compounds have strong clinical evidence for weight reduction but are FDA-regulated drugs requiring a valid prescription and licensed dispensing. Purchasing either through unverified online sellers carries documented risks including dosing inaccuracies, contamination, and absence of medical oversight.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @duongsonmy6 actually say?
Almost nothing medically relevant. The transcript is entirely a birthday celebration: "What a birthday," "I have goosebumps everywhere," "This is out of this world." That is the complete verbal content of the video. There are zero claims about peptides, weight loss, tirzepatide, or semaglutide in the spoken words themselves. The entire medical framing comes from the caption and hashtags, not the creator's mouth.
This is a deliberate content strategy worth naming directly. By keeping the spoken content innocuous, the creator avoids making explicit drug claims while the hashtags do the marketing work. The caption instructs viewers to type "1" to receive a price list and certificate of analysis, which signals this is a sales operation, not an educational account. The "COA" reference implies they are selling compounds they claim have been independently tested.
Does the science back this up?
There is no science to evaluate here because no claims were made. But the product category implied by the hashtags, specifically tirzepatide and semaglutide sold through a DM-based price list, sits in heavily regulated territory with real safety stakes.
Tirzepatide (brand name Mounjaro/Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist. Its efficacy is well-documented. Jastreboff et al. (2022, New England Journal of Medicine) found up to 22.5% body weight reduction in adults with obesity over 72 weeks. Semaglutide data from Wilding et al. (2021, NEJM) showed around 15% weight loss. These are real, significant results from pharmaceutical-grade, regulated products. What cannot be assumed is that any compound sold via TikTok DM carries equivalent purity, dosing accuracy, or safety profile. The FDA has explicitly warned about compounded versions of these drugs, noting contamination and dosing errors as documented risks.
What did they get wrong (or right)?
The creator got nothing medically wrong in speech because they said nothing medical. But the sales architecture around the video raises serious concerns that deserve plain language.
- Selling tirzepatide or semaglutide outside a licensed pharmacy and without a valid prescription is illegal under federal law in the United States, regardless of whether a COA is provided.
- A certificate of analysis from an unverified third-party lab does not equal FDA approval or pharmaceutical-grade manufacturing standards.
- The "type 1 for price list" model is a classic gray-market sales funnel that bypasses the prescriber relationship entirely, meaning no one is screening for contraindications like pancreatitis history, thyroid cancer risk, or drug interactions.
To be fair, the creator never explicitly told anyone to inject anything or skip a doctor. But the funnel they are running makes that outcome structurally likely for buyers who follow through.
What should you actually know?
If you are interested in GLP-1 or GIP-based therapies for weight management, the evidence base is genuinely strong. These are not fringe compounds. But sourcing matters enormously, and this is where the TikTok DM market creates real patient risk.
The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide products, noting reports of adverse events tied to incorrect dosing units, contaminated vials, and products that were not what sellers claimed. The absence of a physician relationship means no one is adjusting your dose if you develop nausea, gastroparesis symptoms, or injection site reactions.
FormBlends operates under licensed medical supervision for a reason. Any peptide or pharmaceutical therapy should involve a clinician who knows your labs, your history, and your goals. A price list sent via DM is not a treatment plan.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide and semaglutide sold via TikTok comments: what's real, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims.
FormBlends verdict
The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims. Both compounds have strong clinical evidence for weight reduction but are FDA-regulated drugs requiring a valid prescription and licensed dispensing. Purchasing either through unverified online sellers carries documented risks including dosing inaccuracies, contamination, and absence of medical oversight.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes tirzepatide and semaglutide through hashtags and a DM-based sales funnel, though the creator makes no spoken medical claims. Both compounds have strong clinical evidence for weight reduction but are FDA-regulated drugs requiring a valid prescription and licensed dispensing. Purchasing either through unverified online sellers carries documented risks including dosing inaccuracies, contamination, and absence of medical oversight.
- Tirzepatide produced up to 22.5% body weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), but those results came from regulated, dosed pharmaceutical products under clinical supervision.
- The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide, citing adverse events from dosing errors and contaminated products sourced outside licensed pharmacies.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Tirzepatide produced up to 22.5% body weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), but those results came from regulated, dosed pharmaceutical products under clinical supervision.
- The FDA issued warnings in 2023 and 2024 about compounded semaglutide and tirzepatide, citing adverse events from dosing errors and contaminated products sourced outside licensed pharmacies.
- Selling tirzepatide or semaglutide without a valid prescription and licensed dispensing is a federal legal violation in the United States, regardless of whether a COA is provided.
- A certificate of analysis from a third-party lab does not equal FDA-grade manufacturing standards, sterility testing, or accurate unit dosing.
- The 'type 1 for price list' DM funnel bypasses any prescriber relationship, meaning no one screens buyers for contraindications like personal or family history of medullary thyroid carcinoma or pancreatitis.
- The video's spoken content contains zero health claims, a deliberate strategy that keeps the creator's words clean while the hashtags and caption do the sales work.
- Patients interested in GLP-1 or GIP-based therapies should pursue them through a licensed telehealth or in-person provider who can review labs, history, and adjust dosing based on response.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
duongsonmy6 · TikTok creator
1.9K views on this video
Type “1” to get price list COA and group link!! Type “1” to get price list COA and group link!! Type “1” to get price list COA and group link!! Type “1” to get price list COA and group link!! #peptide #loseweight #tirzepatide #semaglutide #weightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by duongsonmy6, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.